# Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder

> **NCT03526354** · PHASE4 · COMPLETED · sponsor: **University of Massachusetts, Worcester** · enrollment: 50 (actual)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder
- Substance Use Disorders

## Interventions

- **DRUG:** Brexpiprazole
- **OTHER:** Treatment as Usual

## Key facts

- **NCT ID:** NCT03526354
- **Lead sponsor:** University of Massachusetts, Worcester
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-19
- **Primary completion:** 2024-02-29
- **Final completion:** 2024-02-29
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2025-05-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03526354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03526354, "Controlled Trial of Brexpiprazole For The Treatment of Co-occurring Schizophrenia and Substance Use Disorder". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT03526354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*